Evidence Level
Paraxanthine is a bioactive metabolite of caffeine that has shown potential as a cognitive and performance enhancer. Early research on paraxanthine suggests promising effects, particularly in enhancing mental performance during physical exertion and metabolic regulation.
Yoo et al. (2023) conducted the first dedicated human trial on pure paraxanthine supplementation, demonstrating that a 200mg dose improved sustained attention, reaction time, and short-term memory compared to placebo in a double-blind, crossover design. This study highlights paraxanthine's potential as a cognitive enhancer.
Xing et al. (2021) characterized paraxanthine's pharmacological profile, showing its selective adenosine A2A receptor antagonism, which is the primary mechanism behind caffeine's wakefulness-promoting effects. Unlike caffeine, paraxanthine does not induce broad adrenergic activation, potentially reducing side effects such as anxiety and increased heart rate.
Recent studies have explored paraxanthine's effects in specific contexts. Yoo et al. (2024) found that paraxanthine improved post-exercise cognitive function more effectively than caffeine after a 10-km run, suggesting its utility for maintaining mental performance during physical exertion. Additionally, Gross et al. (2024) reported that 200mg of paraxanthine increased energy expenditure and reduced hunger in adults compared to placebo, indicating potential benefits for metabolic regulation.
Paraxanthine's safety has also been evaluated. The ingredient enfinity, marketed by Ingenious Ingredients, received GRAS status, supporting its safety for commercial use. However, most knowledge about paraxanthine comes from decades of caffeine metabolism research, where it was identified as the principal active metabolite.
Despite these advancements, paraxanthine's standalone effects and optimal dosing remain areas requiring further investigation.